Migraine: anti-CGRP monoclonal antibody may progress to phase 3 trials

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Galcanezumab has a favorable safety and tolerability profile in patients with episodic migraine.

Why this matters

  • Many patients are refractory to migraine prophylaxis , so it is important to always be looking for diverse and novel therapies that may work in these patients.
  • 1 article suggested “cautious excitement” may be warranted for development of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies for the prophylaxis of migraine. 

Study design

  • Randomized controlled study of 410 patients (galcanezumab, n=273; placebo, n=137) with episodic migraine.
  • Funding: None.

Key results

  • Patients in the galcanezumab group reported serious adverse events like appendicitis, Crohn’s disease, suicidal ideation, and congenital ankyloglossia (which occurred in a male infant whose father was treated with galcanezumab).
  • Discontinuation as a result of adverse events was seen in 3 patients in the galcanezumab group because of abdominal pain, visual impairment, and upper limb fracture.
  • Injection-site reactions reported more frequently in the galcanezumab group (P≤.05) and injection-site pain was most common injection-site adverse event (P≤.004).
  • Frequency of upper respiratory tract infection and nasopharyngitis was higher in the galcanezumab group vs placebo group.
  • Hypersensitivity events were seen in 3.3% of patients in the galcanezumab group vs 5.1% in placebo group.

Limitations

  • Short duration of the study.

Coauthored with Anand Ramanathan, PharmD